Merck Weighs New HIV Approval Against Mixed Oncology Trial Results [Yahoo! Finance]
Merck & Company, Inc. (new) (MRK)
Last merck & company, inc. (new) earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.merck.com/home/default.aspx
Company Research
Source: Yahoo! Finance
Merck (NYSE:MRK) received FDA approval for IDVYNSO, a once daily, two drug HIV 1 regimen that is non INSTI and tenofovir free. The new regimen showed non inferior efficacy to the current standard of care in clinical studies. At ASCO, Merck reported that a Welireg based combination did not meet primary endpoints in first line kidney cancer. Merck also shared early data for MK 2010 and BI 1808 plus KEYTRUDA in ovarian cancer, with mixed outcomes across its oncology pipeline. For readers tracking NYSE:MRK, the stock trades at $112.56, with a 1 year return of 47.7% and a 5 year return of 78.6%. Those figures sit alongside shorter term moves that include a 6.2% decline over the past week and a 1.4% decline over the past month, against a 5.7% gain year to date. The FDA approval in HIV and the mixed oncology updates at ASCO both inform how investors may think about Merck's research pipeline and portfolio durability beyond current blockbusters. The combination of a new commercial o
Show less
Read more
Impact Snapshot
Event Time:
MRK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRK alerts
High impacting Merck & Company, Inc. (new) news events
Weekly update
A roundup of the hottest topics
MRK
News
- Kelun-Biotech Announces Three Clinical Study Results Selected for Oral Presentations at 2026 ASCO Annual Meeting [TheStreet.com]TheStreet.com
- Why Merck (MRK) Shares Are Trading Lower Today [Yahoo! Finance]Yahoo! Finance
- FDA Approves Merck's Once-Daily IDVYNSO™ (doravirine/islatravir) [Yahoo! Finance]Yahoo! Finance
- FDA Approves Merck’s Once-Daily IDVYNSO™ (doravirine/islatravir)Business Wire
- Merck Rises 11% YTD: Should Investors Buy, Sell or Hold the Stock? [Yahoo! Finance]Yahoo! Finance
MRK
Earnings
- 2/3/26 - Beat
MRK
Sec Filings
- 4/8/26 - Form ARS
- 4/8/26 - Form DEFA14A
- 4/8/26 - Form DEF
- MRK's page on the SEC website